ITGB1BP2

Across TCGA pan-cancer cohorts, ITGB1BP2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ITGB1BP2 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ITGB1BP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ITGB1BP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, HNSC, and ESCA are the cancer types where ITGB1BP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.224	0.699	.002	12	view →
HNSC	DFS	Median	II,III,IV	0.078	0.695	<.001	9	view →
ESCA	OS	Median	II,III,IV	0.277	0.686	.026	6	view →
UCEC	DFS	Median	II,III,IV	1.000	0.444	.034	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ITGB1BP2–LUAD (OS)

Open the LUAD breakdown →